Status: Recruiting
Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis
Open-label Phase 1b Dose Escalation/Dose Expansion study exploring the safety and efficacy of NXC-201 in patients with relapsed or refractory light chain amyloidosis (AL).
Participants needed: 40
Trial details
Phase: Phase 1, Phase 2Age: 18-120Biological sex: AllType: InterventionalSponsor: Nexcella Inc.Updated: Jul 10, 2025Locations: 18
Eligibility criteria
≥18 years of age. [+12]
Prior treatment with CAR T therapy directed at any target. [+36]